Latigo's Non-Opioid Drug Bests Vicodin, Fueling Hopes in Opioid Crisis

THOUSAND OAKS, CA – July 29, 2026 – In a development that could reshape the landscape of pain management, Latigo Biotherapeutics has announced striking results for its non-opioid pain medicine, LTG-001. A large-scale clinical trial, the results of which were published today in the prestigious New England Journal of Medicine, found the drug to be not only highly effective for acute postoperative pain but also significantly more potent and faster-acting than a commonly prescribed opioid.

The findings represent a major validation for a new class of analgesics and offer a tangible new weapon in the protracted public health battle against the opioid crisis. For the millions who undergo surgery each year, it signals the potential for effective pain control without the looming risk of addiction.

Unpacking a Landmark Trial

The study evaluated LTG-001 in 343 patients experiencing moderate-to-severe pain following abdominoplasty, or “tummy tuck” surgery, a well-established and rigorous model for testing pain medications. The double-blind, randomized trial compared two doses of LTG-001 against both a placebo and a combination of hydrocodone and acetaminophen, widely known by the brand name Vicodin.

The results were unequivocal. The high dose of LTG-001 met the study's primary goal, demonstrating a statistically significant reduction in pain over 48 hours compared to placebo. The drug achieved a Summed Pain Intensity Difference (SPID48) of 62.1, a measure of total pain relief. According to Latigo, this represents the highest analgesic effect ever reported in a published, industry-sponsored abdominoplasty trial.

More strikingly, the high-dose regimen showed an approximately 50% greater analgesic effect than the Vicodin comparator arm. Patients taking LTG-001 also experienced faster relief, with a median onset of meaningful pain reduction at 52 minutes, compared to 83 minutes for those taking the opioid. This combination of superior potency and speed challenges the long-held paradigm of opioids as the most effective first-line defense against severe acute pain.

“From a clinical perspective, the published LTG-001 results... represent an important development in the treatment of acute pain,” said Harold Minkowitz, M.D., of ERG Research, an anesthesiologist and a lead investigator on the study. “While opioids have historically been among the most effective options for treating acute pain, their associated risks underscore the importance of continued research into non-opioid approaches.”

The trial also highlighted the drug's significant opioid-sparing potential. Over half (52.3%) of the patients receiving high-dose LTG-001 remained completely opioid-free for the 48-hour treatment period, more than double the rate of the placebo group (22.1%). Overall, adverse events were reported as mostly mild to moderate, with the total number of events being lower than in the placebo group. However, deeper analysis of the data reveals a slightly higher incidence of fever and presyncope (a feeling of faintness) in the high-dose group compared to placebo, factors that will be closely monitored in future trials.

The Science of Peripheral Pain Blockade

LTG-001 belongs to a novel class of drugs known as selective Nav1.8 inhibitors. These molecules work by blocking a specific sodium channel (Nav1.8) that is found almost exclusively on peripheral pain-sensing neurons. In essence, the drug stops the pain signal at its source, before it can travel to the spinal cord and brain. This targeted, peripheral mechanism is the key to its promise: providing powerful pain relief without the central nervous system side effects—such as euphoria, sedation, and respiratory depression—that lead to opioid addiction and overdose.

The field is not without competition. Vertex Pharmaceuticals' suzetrigine recently became the first Nav1.8 inhibitor to gain regulatory approval, a milestone for the drug class. However, Latigo's data suggests LTG-001 may offer a more robust efficacy profile and a faster onset of action. While the success of any Nav1.8 inhibitor is a win for patients, some experts caution that there may be an upper limit to the pain relief this mechanism can provide. One noted that the observed pain reduction is similar to that of suzetrigine, suggesting a potential "ceiling on the effect of Nav1.8 suppression."

Even so, the ability to provide consistent, meaningful pain relief that rivals or exceeds opioids, without the attendant risks, marks a pivotal moment. The publication in the NEJM—only the second time in 15 years the journal has featured original research on a new acute pain drug—lends significant scientific credibility to Latigo's findings.

A New Weapon in the War on Opioids

The clinical data arrives at a moment of critical need. The opioid crisis continues to exact a devastating toll, and the medical community remains heavily reliant on these drugs for managing postoperative pain. Studies have shown that for some patients, the path to long-term dependency begins with a legitimate prescription after surgery. The availability of a potent, non-addictive alternative could fundamentally alter prescribing habits and prevent countless cases of opioid misuse.

“This publication... adds to the growing scientific understanding of non-opioid approaches to pain management and comes at a time when there is broad recognition of the need for additional treatment options,” said Neil Singla, M.D., chief medical officer of Latigo. The company's CEO, Nima Farzan, has been clear about its mission, stating a dedication to “being part of the solution” to the public health crisis.

The commercial opportunity is immense. The global market for non-opioid pain treatments is projected to grow from over $50 billion in 2026 to more than $70 billion by 2030, driven by intense demand from patients, providers, and payers for safer, effective alternatives.

From Stealth Startup to Public Contender

Latigo Biotherapeutics' journey reflects the high-stakes, high-reward nature of modern drug development. Founded in 2020 and incubated by Westlake Village BioPartners, the company emerged from stealth in early 2024 with a $135 million Series A financing. It quickly followed up with a $150 million Series B round in 2025, bringing its total capital raised to an impressive $290 million from a syndicate of top-tier investors including Blue Owl Capital, 5AM Ventures, and Foresite Capital.

Fueled by this capital and its clinical success, Latigo is moving aggressively. The company filed to go public earlier this month, seeking to list on the Nasdaq under the ticker “LTGO.” The proceeds are intended to fund a pivotal Phase 3 program for LTG-001, which is slated to begin in the second half of this year with a trial in patients undergoing bunionectomy—a standard model for FDA approval in acute pain.

Latigo's ambitions extend beyond LTG-001. The company is also developing an intravenous formulation to bridge inpatient and outpatient care, as well as a pipeline of next-generation Nav1.8 inhibitors for both acute and chronic pain indications like osteoarthritis. This strategic approach suggests a long-term vision to build a franchise centered on non-addictive pain solutions. With its lead candidate having now proven its mettle against a formidable opioid comparator, Latigo is poised to become a significant force in the future of pain medicine.